Abstract. Overexpression of ErbB2 has been frequently found in mammary carcinoma. We have previously shown that the aberrant activation of H-Ras induces human breast cell invasion and migration. The present study was aimed at investigating the effect of ErbB2 overexpression on H-Ras-induced breast cell invasion and to elucidate the underlying mechanisms. Herein, we show that overexpression of ErbB2 promotes invasive and migratory abilities of H-Ras-activated MCF10A human breast epithelial cells through upregulation of matrix metalloproteinase (MMP)-13 and urokinase-type plasminogen activator (uPA). We also demonstrate that the p38 MAPK is an important signaling molecule in the ErbB2-induced upregulation of MMP-13 and uPA and invasion/migration of H-Ras MCF10A cells overexpressing ErbB2. The present study elucidating the molecular mechanism underlying ErbB2-induced promotion of H-Ras MCF10A cell invasion may provide invaluable information for understanding breast cancer progression and establishing therapeutic interventions for breast cancer.

Introduction

The metastatic spread of the disease is the major cause of death from breast cancer. Since genetic alterations can contribute to the progression and metastasis of breast cancer, studies on the molecular mechanisms involved in breast cancer invasion are important for the identification of genes that augment the metastatic or invasive potential of breast cancer cells. ErbB2 (also known as HER-2/neu) is the oncogenic receptor tyrosine kinase which has extensive sequence homology to epidermal growth factor receptor (1,2). ErbB2 signaling can promote malignant transformation, in part, by Ras activation (3,4). Extracellular stimuli that act on ErbB2 cause transient activation of Ras which in turn activates multiple downstream effectors that stimulate cytoplasmic signaling cascades that regulate a variety of malignant processes including cell proliferation, invasion and migration (5-7). Amplification or overexpression of ErbB2 has been found in 20-30% of human breast cancers (8). Mounting evidence indicates that overexpression of ErbB2 plays an important role in human breast cancer metastasis (9-13).

Invasive and metastatic processes of malignant tumor require the expression and activation of matrix metalloproteinases (MMPs) which induce the progression of tumor cells including degradation of the extracellular matrix and basement membrane (14). Human MMP gene family contains more than 20 members (15,16). Expressions of MMP-2 and MMP-9 have been shown to be associated with the progression of metastasis (17,18). MMP-13 is expressed in breast carcinomas and head and neck squamous cell carcinomas and its expression correlates with invasion of these carcinomas (19,20). Urokinase-type plasminogen activator (uPA) represents a second extracellular proteolytic system which is known to play a critical role in tumor invasion and metastasis (21,22). Co-expression of MMPs and uPA was observed during tumor invasion and metastasis (23-25). ErbB2 activation induces the transcriptional activation of uPA and MMPs (26,27) and regulates expression and activity of these proteases in breast cancer cell lines and breast cancer patients (9,28-31). We have previously shown that ErbB2 induces invasive and migratory phenotypes for which MMP-9 is responsible in MCF10A human breast epithelial cells (32).

Mutations of the ras gene are among the most frequent genetic alterations in human tumors (33). Although ras mutations are rarely seen in breast cancers, aberrant Ras activation may promote breast cancer development (34,35). The single point mutation at amino acid residue 12 (Gly to Asp) of H-Ras is often found in mammary carcinoma (36). Using MCF10A cell system in which H-Ras is constitutively activated, we showed that H-Ras activation induced invasive and migratory phenotypes (37). We also showed that up-regulation of MMP-2 was crucial to the H-Ras-induced phenotypic changes (38,39).

In order to determine the effect of ErbB2 overexpression on H-Ras-induced breast cell invasion and the underlying mechanisms, we investigated the invasiveness of H-Ras...
MCF10A cells overexpressing ErbB2 and the involvement of various proteases. Herein we report that ErbB2 enhances invasion and migration of H-Ras MCF10A cells through MMP-13 and uPA. We further show that p38 MAPK signaling pathway plays a critical role in the ErbB2-enhanced invasiveness and upregulation of MMP-13 and uPA in H-Ras-activated human breast cells.

Materials and methods

Cell lines. Development and characterization of H-Ras MCF10A cells have been described previously (37). The H-Ras MCF10A cell line overexpressing ErbB2 (ErbB2-H-Ras MCF10A cell line), was kindly provided by Dr K.W. Kang (Chosun University, Gwang-Ju, Korea), was established using an MSCV-GFP retrovirus system as previously described (40). Cells were cultured in DMEM/F12 medium supplemented with 5% horse serum, 0.5 μg/ml hydrocortisone, 10 μg/ml insulin, 20 ng/ml epidermal growth factor, 0.1 μg/ml cholera enterotoxin, 100 U/ml penicillin-streptomycin, 2 mM L-glutamine and 0.5 μg/ml amphotericin B.

In vitro invasion assay. In vitro invasion assay was performed using a 24-well transwell unit with polycarbonate filters (Corning Costar, Cambridge, MA) as previously described (38). Cells were placed in the upper part of the transwell plate, incubated for 18 h, fixed with methanol and stained with hematoxylin for 10 min followed briefly by eosin. The invasive phenotypes were determined by counting the cells that migrated to the lower side of the filter with microscopy at x400. Thirteen fields were counted for each filter and each sample was assayed in triplicate.

In vitro migration assay using transwell. In vitro migration assay was performed using a 24-well transwell unit with polycarbonate filters as previously described (38). Experimental procedures are the same as the in vitro invasion assay described above except that the filter was not coated with Matrigel.

Knockdown of MMP-13 and uPA by small-interfering (si) RNA. An siRNA targeting MMP-13 (5'-AUUUCUCGGGA CCUCAGCuAUGG-3') and an siRNA targeting uPA (5'-UAUAUCUUCUGAGAGGAAGGAGGGC-3') were purchased from Invitrogen (Carlsbad, CA, USA). Cells in the exponential phase of growth were plated in six-well plates at 2x10⁵ cells/well, grown for 24 h then transfected with 100 pmol siRNA for 6 h using Lipofectamine 2000 reagent and OPTI-MEMI reduced serum medium (Invitrogen). Control cells were transfected with Stealth™ RNAi negative control duplex (Invitrogen).

Rac1 activity assay. The levels of Rac1-GTP were measured by affinity precipitation using PAK-1 PBD Rac assay reagent (Upstate Biotech. Inc., Lake Placid, NY) following manufacturer’s instruction as previously described (41,50). Proteins were separated by 12% SDS-PAGE, transferred to nitrocellulose membrane, and blotted with anti-Rac1 antibody.

Raf-1 activity assay. The Raf-1 activity was measured as previously described (50). Briefly, cell lysates were preincubated with protein A-agarose suspension (Roche, Basel, Switzerland). The supernatant was incubated with anti-Raf-1 antibody. Protein A-agarose suspension was added and incubation was extended overnight on ice with shaking. The antibody-antigen complex was washed twice in lysis buffer and twice in high salt buffer and then the SDS-PAGE loading buffer was added. Immunoblot analysis was performed to assess the activity of immunoprecipitated Raf-1 with anti-phosphorylated Raf-1 antibody.

Reverse transcription (RT)-PCR. RNA was reverse transcribed with RT-Superscript III reverse transcriptase (Invitrogen). MMP-1, MMP-2, MMP-3, MMP-7, MMP-8 MMP-9, MMP-13 and uPA were synthesized by RT-PCR using the following primers: MMP-1: sense 5'-GGAGGG GATGCTCTTTTGTAG-3' antisense 5'-TACGAAAAGAC CAAAAGGGAGC-3', MMP-2: sense 5'-AATGGCCCAT CCCGATAACC-3' antisense 5'-AAACCTTCAGGTCCCTTTCA GAC-3', MMP-3: sense 5'-CCTGCTTGTTGCTCTTTAGTGC-3' antisense 5'-GAGCTACAATCCCGGAAAGC-3', MMP-7: sense 5'-ATGTTAAACTCCCGCGTCATA-3' antisense 5'-ACGATAAGAGAAGTCATCC-3', MMP-8: sense 5'-TGG ACCCAATGGAATCTTTGCG-3' antisense 5'-ATAACGG ACTCAGAGCCAGCA-3', MMP-9: sense 5'-TCTGCC AGTACGAGGAAAGG-3' antisense 5'-AGGATGTGATA TAGGTCAGG AG-3', MMP-13: sense 5'-TGTTTGTGGT CGGATGTTCCGCT-3' antisense 5'-GGGTGCTCATAT GCAGCATA-3', uPA: sense 5'-CAGCCAGGAAGGAGG-3' antisense 5'-AAACCTTCAGGTCCCTTTCA GAC-3', ubiquitin: sense 5'-ACGACATTGTTGCTGACTTT-3'. Thermocycler conditions were as previously described (42).

Results

ErbB2 overexpression enhances invasive and migratory abilities of H-Ras MCF10A cells. To investigate the effect of ErbB2 on the invasion and migration of H-Ras-activated MCF10A cells, ErbB2 gene was introduced into H-Ras MCF10A cells by transfection, resulting a stable cell line ErbB2-H-Ras MCF10A. The intrinsic level of ErbB2
expression was low in H-Ras MCF10A cells. Overexpression of ErbB2 in ErbB2-H-Ras MCF10A cells was confirmed by Western blot analysis (Fig. 1A). Overexpression of ErbB2 caused significant increases in invasiveness and migration of H-Ras MCF10A cells, demonstrating that ErbB2 enhanced invasive and migratory abilities of H-Ras MCF10A cells (Fig. 1B).

ErbB2 upregulates MMP-13 and uPA. Our previous report has shown that ErbB2 induces upregulation of MMP-9 in the parental MCF10A cells (32). The present study investigated the effect of ErbB2 on the expression of various proteases in H-Ras MCF10A cells by RT-PCR analysis. As shown in Fig. 2A, the expression of mRNAs of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-13 and uPA was observed in H-Ras MCF10A and ErbB2-H-Ras MCF10A cells. The mRNAs of MMP-1, MMP-3, MMP-7 and MMP-8 were detected neither in H-Ras MCF10A cells nor in the ErbB2-H-Ras MCF10A cells (data not shown). The levels of MMP-2 and MMP-9 were strong in H-Ras MCF10A cells as previously reported (37) while the levels of MMP-13 and uPA were weak in these cells. The mRNA levels of MMP-13 and uPA were markedly increased by ErbB2 overexpression. The mRNA level of MMP-2 was not altered and the MMP-9 mRNA level was decreased in ErbB2-H-Ras MCF10A cells. The data from RT-PCR were confirmed by Western blot analysis (Fig. 2B), clearly demonstrating that among the proteases tested, MMP-13 and uPA were upregulated by ErbB2 overexpression in H-Ras MCF10A cells. We then asked whether ErbB2 upregulated MMP-13 and uPA in the parental MCF10A cells. As shown in Fig. 2C, the mRNA levels of MMP-13 and uPA were increased by ErbB2 in MCF10A cells. These results suggest that MMP-13 and uPA may be involved in the ErbB2-enhanced invasive and migratory phenotypes in human breast epithelial cells.

MMP-13 and uPA are critical to the ErbB2-enhanced invasion and migration. In order to determine the functional significance of MMP-13 and uPA in the invasion and migration of ErbB2-H-Ras MCF10A cells, we selectively knocked down the expression of MMP-13 or uPA using an siRNA approach. Inhibition of MMP-13 or uPA by siRNA
molecules targeting these genes was proven by Western blot analysis (Fig. 3A). Following MMP-13 knock-down, invasiveness of ErbB2-H-Ras MCF10A cells was significantly inhibited by 41% as determined by in vitro invasion assay (Fig. 3B, left). A similar extent of inhibition in invasion (43.7%) was observed when uPA expression was knocked-down. Similarly, ErbB2-H-Ras MCF10A cell motility was inhibited by knock-down of MMP-13 and uPA by 43.7 and 36.9%, respectively (Fig. 3B, right). The results demonstrate that MMP-13 and uPA play critical roles in ErbB2-enhanced cell invasion and migration in H-Ras MCF10A cells.

ErbB2-induced MMP-13 and uPA upregulation is mediated by p38 MAPK. In order to investigate the specific roles of signaling pathways in the upregulation of MMP-13 and uPA by ErbB2, we detected the activation of signaling molecules in ErbB2-H-Ras MCF10A cells. As shown in Fig. 4, the phosphorylation of p38 MAPK was increased by ErbB2, while the levels of active Raf1, phosphorylated MEK, ERK-1/2, Rac1, Akt were not affected. These results indicate that the p38 MAPK signaling pathway may be involved in the enhancing effect of ErbB2 on H-Ras MCF10A cell invasion and migration.

We then examined the functional role of p38 MAPK signaling in MMP-13 and uPA expressions and invasive/migratory phenotypes of ErbB2-H-Ras MCF10A cells. Treatment with 50 μM of SB203580, a pharmacological inhibitor of p38 MAPK, significantly inhibited the expression levels of MMP-13 and uPA (Fig. 5A), indicating that the activation of p38 MAPK is critical to the upregulation of MMP-13 and uPA by ErbB2. Moreover, invasion and migration of ErbB2-MCF10A cells were significantly inhibited by treatment with 50 μM of SB203580 by 37.3 and 45.7%,
respectively (Fig. 5B). These results demonstrate that p38 MAPK signaling pathway plays a critical role in the ErbB2-mediated upregulation of MMP-13 and uPA as well as in the ErbB2-promoted invasive and migratory abilities of H-Ras MCF10A cells.

Discussion

Breast cancer is one of the most frequent malignancies in women and the major cause of death from breast cancer is the metastatic spread of the disease from the primary tumor to distant sites in the body. Since about 20-30% of human breast cancers show amplification or overexpression of ErbB2 (43) and overexpression of ErbB2 plays an important role in human breast cancer metastasis, this study aimed to investigate the effect of ErbB2 overexpression on H-Ras-induced breast cell invasion and to elucidate the underlying mechanisms. Recent studies demonstrate that there is a close association between ErbB2 and Ras activation (7,44). ErbB2 overexpression is correlated with the increased Ras-GTP formation in breast tumor tissues and cell lines (4,45). On the other hand, constitutively activated K-Ras and amplification of C-ErbB2 seem to occur independently in the process of colon tumor progression (46). Here, we show that invasive and migratory abilities of H-Ras MCF10A cells were significantly increased by ErbB2 overexpression, indicating the enhancing effect of ErbB2 on H-Ras-induced malignant phenotypic changes.

A linkage between ErbB2 activation and tumor progression was shown to be mediated by MMP family members. ErbB2 increases invasive capacities of malignant cancer cell lines by stimulating the expressions of uPA (47), uPAR (48), MMP-1 (26), MMP-2 (47), MMP-7 (47), MMP-9 (47) and MMP-13 (49). The present study demonstrates that ErbB2 overexpression increases the expressions of MMP-13 and uPA in H-Ras MCF10A cells (Fig. 2). Using siRNA knockdown approach, we revealed MMP-13 and uPA as important players in the ErbB2-induced invasion and migration of H-Ras MCF10A cells. In consistent with our results, overexpression of uPA in ErbB2-positive breast cancer tissues has been shown to determine the aggressive and metastatic clinical behaviors (31).

Activation of H-Ras induces expressions of MMP-2 and MMP-9 in MCF10A cells as shown in Fig. 2 and in our previous report (37). ErbB2 overexpression induces the expression of MMP-9 but not that of MMP-2 in these cells (32). Our results show that the H-Ras-induced MMP-2 expression was not affected by ErbB2 overexpression. Interestingly, the expression of MMP-9 in H-Ras-activated cells was significantly decreased by overexpression of ErbB2 (Fig. 2). These data indicate that the single activation of ErbB2 or H-Ras enhances MMP-9 expression while the co-expression of ErbB2 and H-Ras inhibits MMP-9 expression. The results suggest that crosstalk between ErbB2 and H-Ras signaling may suppress the expression of MMP-9.

Among signaling molecules tested, ErbB2 activates p38 MAPK in H-Ras MCF10A cells (Fig. 4). Functional significance of p38 MAPK signaling in invasive and migratory phenotypes was demonstrated in ErbB2-H-Ras MCF10A cells (Fig. 5). Given that p38 MAPK has been shown to be essential for the H-Ras-induced invasive phenotype of MCF10A cells (38,50), the results obtained in this study and our previous studies indicate a key role for p38 MAPK signaling pathway in breast cell invasion.

It has been shown that the induction of MMP-13 expression in human skin fibroblasts is mediated by p38 MAPK (51). The p38 MAPK pathway plays a crucial role in expression of MMP-13 and invasive phenotype of transformed squamous epithelial cells (52). The p38 MAPK pathway is required for the secretion of uPA from ovarian cancer cells (53). Activation of p38 MAPK by H-Ras induces MMP-2 upregulation (38,39). This study demonstrates that the additional activation of p38 MAPK by ErbB2 resulted in upregulation of MMP-13 and uPA while the level of MMP-2 expression was not altered. These results suggest that p38 MAPK activation by H-Ras alone is not sufficient for the upregulation of MMP-13 and uPA which may require a stronger activity of p38 MAPK signaling by the combined action of ErbB2 and H-Ras. A possibility still remains that ErbB2 can also contribute to the activation of signaling pathway(s) other than the p38 MAPK which may lead to the upregulation of MMP-13 and uPA. Further studies need to be performed to elucidate the detailed mechanisms underlying the ErbB2-induced upregulation of MMP-13 and uPA in H-Ras-activated breast cell system.

Taken together, the present study demonstrates that ErbB2 promotes invasive and migratory abilities of H-Ras-activated human breast epithelial cells through MMP-13 and uPA. We also show that the p38 MAPK is an essential signaling molecule in the induction of MMP-13 and uPA and invasion of H-Ras MCF10A cells overexpressing ErbB2. Given that the overexpression of ErbB2 and the activating mutation of H-Ras have been often found in mammary carcinoma, the present study elucidating the molecular mechanism underlying ErbB2-induced promotion of H-Ras MCF10A cell invasion may provide invaluable information for understanding breast cancer progression and establishing therapeutic interventions for breast cancer.

Acknowledgements

This study was supported by the KOSEF NRL Program (MEST, no. ROA-2008-000-20070-0).

References

22. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The
19. Cazorla M, Hernández L, Nadal A, Balbín M, López JM,
17. Tryggvason K, Hoyhtya M and Pyke C: Type IV collagenases
16. Deryugina EI and Quigley JP: Matrix metalloproteinases and
15. Liotta LA and Kohn EC: Stromal therapy: the next step in
14. MacDougall JR and Matrisian LM: Contributions of tumor and
12. Kawa S, Matsushita H, Ohbayashi H, Semba K and Yamamoto T:
11. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA,
10. Bange EZ and Ullrich A: Molecular targets for breast cancer
8. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG,
7. Algül H, Wagner M, Lesina M and Schmid RM: Over-
expression of ErbB2 in the exocrine pancreas induces an
inflammatory response but not increased proliferation. Int J Cancer
7. Algül H, Wagner M, Lesina M and Schmid RM: Over-
expression of ErbB2 in the exocrine pancreas induces an
inflammatory response but not increased proliferation. Int J Cancer

22. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The
19. Cazorla M, Hernández L, Nadal A, Balbín M, López JM,
17. Tryggvason K, Hoyhtya M and Pyke C: Type IV collagenases
16. Deryugina EI and Quigley JP: Matrix metalloproteinases and
15. Liotta LA and Kohn EC: Stromal therapy: the next step in
14. MacDougall JR and Matrisian LM: Contributions of tumor and
12. Kawa S, Matsushita H, Ohbayashi H, Semba K and Yamamoto T:
11. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA,
10. Bange EZ and Ullrich A: Molecular targets for breast cancer
8. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG,


